Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II

Bimekizumab Impact on Patient-Reported Outcomes in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II

Abstract Introduction Hidradenitis suppurativa (HS) symptoms (pain, itch, odour and drainage) impair quality of life (QoL). Bimekizumab, a humanised IgG1 monoclonal antibody, selectively inhibits interleukin (IL)-17A and IL-17F. The impact of bimekizumab on patient-reported outcomes (PROs) was asses...

Full description

Saved in:
Bibliographic Details
Main Authors: Vivian Y. Shi, John R. Ingram, Hadar Lev-Tov, Sylke Schneider-Burrus, Seth Forman, Martina L. Porter, Koremasa Hayama, Linnea Thorlacius, Jérémy Lambert, Tom Vaux, Bartosz Lukowski, Robert L. Rolleri, Jacek C. Szepietowski
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-07-01
Series:Dermatology and Therapy
Subjects:
BE HEARD
Bimekizumab
DLQI
Hidradenitis suppurativa
HiSQOL
HSSDD
Online Access:https://doi.org/10.1007/s13555-025-01465-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s13555-025-01465-4

Similar Items